RxSight, Inc. (NASDAQ: RXST) — Business Overview

Executive Summary

RxSight, Inc. is a commercial-stage ophthalmic medical device company that has created a genuinely novel category within cataract surgery: the only FDA-approved intraocular lens (IOL) whose refractive power can be fine-tuned after implantation, rather than being fixed at the time of surgery. The company's platform pairs a proprietary Light Adjustable Lens ("LAL"/"LAL+") with a companion capital device, the Light Delivery Device ("LDD"), that uses UV light to reshape the lens in-office over a series of post-operative visits. This "razor-and-blade" model — placing LDD consoles with premium cataract surgeons and then selling a recurring stream of single-use LALs — has driven RxSight from a niche technology story to a company with roughly 1,134 LDDs installed and approximately 300,000 LALs implanted since inception through December 31, 2025. Full-year 2025 revenue was $134.5 million, down 4% from $139.9 million in 2024, as the business worked through a slower-than-expected ramp in new capital placements and uneven utilization among existing accounts. Gross margin nonetheless expanded to 76.6% (from 70.7%), reflecting manufacturing leverage and a richer mix, even as the company continued to post a net loss ($38.9 million for 2025) while it invests in R&D ($38.5 million) and a direct U.S. sales organization ($112.7 million of SG&A). RxSight ended 2025 with $228.1 million of cash and short-term investments — a substantial runway — but faces intensifying competition from much larger incumbents (Alcon and Johnson & Johnson Vision), lengthening capital-equipment sales cycles, and investor skepticism about the durability of its growth algorithm after two guidance cuts in 2025. The core investment debate is whether RxSight's clinical differentiation and growing LDD installed base constitute a durable, defensible moat in premium cataract surgery, or whether its technology edge will be competed away by vastly better-resourced rivals before the installed base reaches critical mass.

---

1. Core Business Model

RxSight's value proposition rests on a simple but clinically important insight: cataract surgeons cannot perfectly predict a patient's post-surgical refractive outcome before implanting a lens. Conventional premium IOLs are fixed-power and must be selected pre-operatively using biometric formulas that carry inherent error. The RxSight system instead defers the final power decision until after the eye has healed, when the actual refractive outcome can be measured and the lens adjusted non-invasively using light.

   STEP 1                      STEP 2                           STEP 3
 ------------               -----------------                -----------------
|  Light      |            |  Post-Surgery UV |              |  Customized     |
|  Adjustable | --implant->|  Light Delivery   | --repeat---> |  Vision         |
|  Lens (LAL) |  during    |  Device (LDD)     |  adjustments |  Correction     |
|  inserted   |  standard  |  reshapes the     |  over 2-3    |  locked in via  |
|  in capsular|  cataract  |  photosensitive   |  weeks based |  final "lock-in"|
|  bag        |  surgery   |  lens material    |  on measured |  UV treatment   |
|             |            |  in-office         |  refraction  |                 |
 ------------               -----------------                -----------------

Mechanically: the LAL is made of a proprietary photosensitive silicone material. Two to three weeks after implantation, once the eye has stabilized and refraction can be measured with patient feedback (reading an eye chart, adjusting focus interactively), the surgeon uses the LDD to project a defined UV light pattern onto the lens, altering its curvature and optical power in increments as fine as 0.25 diopter. The company's FDA pivotal trial data cited in the 10-K show an average of 1.6 adjustment treatments per patient, followed by one or two "lock-in" UV treatments that permanently fix the final prescription (polymerizing the remaining photosensitive monomers so no further change is possible). In that pivotal trial, 70.1% of LAL patients achieved 20/20 or better uncorrected distance visual acuity — a materially higher rate than typically reported for fixed-power premium IOLs — without the increased glare/halo complaints associated with some multifocal/EDOF lens designs.

Commercially, RxSight sells on a razor-and-blade model: a new customer (almost always an ambulatory surgical center, occasionally a hospital) typically purchases or leases an LDD console, enters an LAL consignment agreement, and then is billed per LAL as cases are performed. This creates a durable recurring-revenue relationship once a surgeon is trained and comfortable with the post-operative light-adjustment workflow, but it also means growth depends on two distinct and sequential sales motions: (1) placing new capital equipment with surgeons, and (2) driving utilization/ramp of LAL volume per installed LDD — the latter being the primary swing factor in 2025's revenue shortfall.

2. Business Segments

RxSight operates and reports as a single operating segment: the design, manufacture, and commercialization of light-adjustable intraocular lenses and the companion light delivery system for the treatment of refractive error following cataract surgery. The company does not break out discrete reporting segments in its financial statements; instead, management and investors monitor two de facto product lines within that single segment:

• Capital/Instrument revenue — sales (and in some cases placements) of the Light Delivery Device to new and existing accounts. This is the "installed base growth" engine and is lower-margin, more capital-cycle-sensitive, and the component most affected by lengthening purchase decision timelines in 2025.
• Consumable/Procedure revenue — sales of the Light Adjustable Lens itself, which scale with the number of LAL-based cataract procedures performed across the installed LDD base. This is the higher-margin, recurring component and the primary driver of long-term unit economics once an LDD is placed and surgeons are trained.

Geographically, the overwhelming majority of revenue is generated in the United States, where RxSight maintains a direct sales force targeting the roughly 3,500–4,000 highest-volume premium cataract surgeons; the company has also obtained regulatory approvals and begun limited commercialization in Europe, Canada, Mexico, Singapore, Australia, and South Korea, though international revenue remains a small portion of the total.

3. Product Portfolio

4. Competitive Landscape

RxSight's core competitive challenge is scale asymmetry: it competes in premium cataract surgery against two of the largest ophthalmic franchises in the world. Per the 10-K, Alcon and Johnson & Johnson Vision together account for roughly 75% of the U.S. premium cataract IOL market, and both are explicitly described by RxSight as "significantly larger" competitors with far greater commercial, manufacturing, and R&D resources. Bausch + Lomb is a smaller but relevant third incumbent in premium/presbyopia-correcting IOLs. None of these competitors offers a direct, FDA-approved equivalent to light-adjustable, post-operative power correction — RxSight's principal source of clinical differentiation — but all compete aggressively on fixed-power multifocal, extended-depth-of-focus (EDOF), and toric premium lens technology that is easier for surgeons to adopt (no capital equipment, no multi-visit adjustment workflow) and backed by much larger sales forces and surgeon relationships.

                     HIGH REFRACTIVE PRECISION / CUSTOMIZATION
                                      ^
                                      |
                              RxSight (LAL/LDD)
                              [post-op adjustable,
                               but new workflow &
                               capital equipment]
                                      |
   NARROW  <-------------------------+-------------------------->  BROAD
   PRODUCT                           |                          PORTFOLIO /
   LINE                              |                          SCALE
                     Bausch + Lomb   |      Alcon
                  (premium IOLs,     |   (PanOptix, Vivity;
                   smaller scale)    |    largest IOL franchise)
                                      |
                              Johnson & Johnson Vision
                              (TECNIS platform; broad
                               surgical + vision portfolio)
                                      |
                                      v
                     LOW REFRACTIVE PRECISION / FIXED AT SURGERY

RxSight's defensible position sits in the upper-left-to-center of this matrix: unmatched post-operative customization, but a narrower, single-platform product line versus the broad, multi-technology portfolios of Alcon and J&J. The 2025 slowdown in LDD placements — down 47% in units for the year, with management citing lengthening capital-equipment purchase cycles and slower ramp among newer accounts — illustrates how competitors' simpler, no-capital-commitment premium lenses can win share of surgeon attention even where RxSight's clinical outcomes data is favorable.

5. Strategic Strengths & Risks

Strengths

• Category-defining IP and regulatory moat: RxSight holds the only FDA-approved adjustable-power IOL platform; patents covering the lens, delivery device, and adjustment methods extend into the 2033–2045 range, and the ~55 cumulative supplemental FDA approvals obtained through 2025 (including the LAL+ line extension) demonstrate sustained regulatory and R&D execution that would be costly and time-consuming for a new entrant to replicate.
• Favorable clinical outcomes data: 70.1% of trial patients achieving 20/20-or-better uncorrected vision, without elevated glare/halo complaints, is a differentiated clinical story relative to many fixed-power premium lenses.
• Recurring, high-margin consumable revenue once adopted: LAL unit volume grew 12% in 2025 even as capital (LDD) sales fell sharply, showing that once surgeons are trained, utilization among the existing base continues to grow — the installed base is "sticky" in aggregate even when new placements slow.
• Strong balance sheet: $228.1 million in cash and short-term investments at year-end 2025 provides multi-year runway to continue funding commercial execution and R&D without near-term dependence on capital markets.
• Vertically integrated, FDA-cleared manufacturing base in Aliso Viejo, CA, supporting quality control and a defensible supply chain for the core LAL/LDD technology (notwithstanding reliance on single/sole-source component suppliers and third-party sterilization).

Risks

• Capital-equipment sales-cycle sensitivity: Revenue growth depends on placing LDD consoles, a discretionary capital purchase for ambulatory surgical centers; 2025 showed how quickly placement cadence can slow (LDD units down 47% year-over-year) when surgeon ROI conviction or capital budgets tighten.
• Scale disadvantage vs. Alcon and J&J Vision: With ~75% combined U.S. premium-IOL share and far larger sales forces, R&D budgets, and surgeon relationships, incumbents can out-market and out-resource RxSight even where its technology is differentiated.
• History of net losses: RxSight has never been profitable ($38.9 million net loss in 2025) and explicitly discloses it may not achieve or sustain profitability; continued elevated SG&A ($112.7 million in 2025) to fund the direct sales force is a persistent drag.
• Guidance credibility / execution risk: The company cut full-year 2025 guidance meaningfully mid-year (from an initial $160–175 million range down toward the $120–130 million area) following Q1 and Q2 underperformance, and 2026 guidance of $120–135 million implies, at the midpoint, roughly flat-to-down revenue versus 2025 — raising investor questions about near-term growth visibility.
• Reimbursement and regulatory exposure: Scheduled Medicare payment reductions (2% annually through 2032 absent Congressional action) and evolving FDA/EU MDR post-market obligations create ongoing policy and compliance risk around procedure economics.
• Customer ramp unevenness: Management has disclosed that newer accounts are ramping more slowly than historical cohorts while some older accounts are flat-to-declining, suggesting surgeon training/utilization — not just unit placements — is now the critical constraint on growth.

6. Financial Overview

All figures below are as reported in RxSight's FY2025 Form 10-K (filed with the SEC, fiscal year ended December 31, 2025) and the company's Q4/FY2025 earnings release.

R&D expense by year, as disclosed: $29.1 million (2023), $34.4 million (2024), $38.5 million (2025) — a steady increase reflecting continued investment in the LAL+ platform and related clinical/regulatory work. Employee headcount stood at 461 full-time employees as of December 31, 2025.

7. Summary Conclusion

RxSight has built something genuinely rare in medical devices: a clinically validated, FDA-approved technology platform with no direct functional equivalent on the market, protected by patents running into the 2040s and by the practical difficulty of replicating an adjustable-lens-plus-capital-device ecosystem. The 12% growth in LAL consumable volume during 2025 — even as capital placements stalled — is the clearest evidence that the installed base, once trained, continues to generate durable, high-margin recurring revenue. That is the bull case: a small, differentiated company slowly converting high-volume premium cataract surgeons into a growing annuity stream, with a strong balance sheet ($228 million in cash) to fund the multi-year sales and training cycle required.

The bear case is equally concrete. RxSight is a sub-scale commercial organization competing for surgeon mindshare against Alcon and Johnson & Johnson Vision, companies with vastly larger sales forces, broader premium-lens portfolios, and the ability to bundle simpler, no-capital-equipment alternatives. 2025's two guidance cuts, the 47% decline in LDD placements, and management's own acknowledgment of lengthening capital sales cycles and uneven account ramps show that clinical superiority alone has not been sufficient to sustain the growth algorithm investors previously underwrote. The next several quarters — specifically, whether new accounts ramp utilization faster under RxSight's revised clinical-support-led commercial strategy, and whether LDD placement cadence stabilizes — will determine whether RxSight's technological moat translates into durable market share gains or whether it remains a differentiated niche within a market the two incumbents continue to dominate.